MOLECULAR GENETIC FEATURES OF PERITONEAL PSEUDOMYXOMA


Cite item

Full Text

Abstract

The article analyzes the modern molecular genetic features pseudomyxoma of the peritoneum in order to find a possible source and causes of disease, identify the factors of tumor growth, as well as identification of ways to improve current treatments.

About the authors

N. K Shahpazyan

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Mrdical Sciences

115478, Moscow, Russian Federation

A. G Abdullayev

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Mrdical Sciences

Email: agulsky@rambler.ru
канд. мед. наук, науч. сотр. отд-ния хирургического торакального НИИ клинической онкологии 115478, Moscow, Russian Federation

B. E. Polotskiy

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Mrdical Sciences

115478, Moscow, Russian Federation

L. V Mekheda

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Mrdical Sciences

115478, Moscow, Russian Federation

M. I. Davydov

N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Mrdical Sciences

115478, Moscow, Russian Federation

References

  1. Chejfec G., Rieker W.J., Jablokow V.R. et al. Pseudomyxoma peritonei associated with colloid carcinoma of the pancreas. Gastroenterology. 1986; 90: 202-5.
  2. Hawes D., Robinson R., Wira R. Pseudomyxoma peritonei from metastatic colloid carcinoma of the breast. Gastrointest. Radiol. 1991; 16: 80-2.
  3. Kahn M.A., Demopoulos R.I. Mucinous ovarian tumors with pseudomyxoma peritonei: a clinicopathological study. Int. J. Gynecol. Pathol. 1992; 11: 15-23.
  4. Ronnett B.M., Seidman J.D. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am. J. Surg. Pathol. 2003; 27: 650-7.
  5. Guo A.T., Song X., Wei L.X., Zhao P. Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J. Gastroenterol. 2011; 17(30): 3531-7.
  6. Szych C., Staebler A., Connolly D.C., Wu R., Cho K.R., Ronnett B.M. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am. J. Pathol. 1999; 154(6): 1849-55.
  7. Shin J.H., Bae J.H., Lee A., Jung C.K., Yim H.W., Park J.S., Lee K.Y. CK7, CK20, CDX2 and MUC2 immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J. Clin. Oncol. 2010; 40(3): 208-13.
  8. Ferreira C.R., Carvalho J.P., Soares F.A., Siqueira S.A., Carvalho F.M. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. Int. J. Gynecol Cancer. 2008; 18(1): 59-65.
  9. O’Connell J.T., Tomlinson J.S., Roberts A.A., McGonigle K., Barsky S.H. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am. J. Pathol. 2002; 161: 551-64.
  10. Taflampas P., Dayal S., Chandrakumaran K., Mohamed F., Cecil T.D., Moran B.J. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients. Eur. J. Surg. Oncol. 2014 Jan 12. pii: S0748-7983(14)00005-5.
  11. Baratti D., Kusamura S., Nonaka D., Cabras A.D., Laterza B., Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann. Surg. 2009; 249(2): 243-9.
  12. Chang M.S., Byeon S.J., Yoon S.O., Kim B.H., Lee H.S., Kang G.H., Kim W.H., Park K.J. Leptin, MUC2 and mTOR in appendiceal mucinous neoplasms. Pathobiology. 2012; 79(1): 45-53.
  13. Zou Y., Wang F., Liu F. Y., Huang M.Z., Li W., Yuan X.Q., Huang O.P., He M. RNF43 RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer. Gene. 2013; 531(1): 112-6.
  14. Nishikawa G., Sekine S., Ogawa R., Matsubara A., Mori T., Taniguchi H. et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br. J. Cancer. 2013; 108(4): 951-8.
  15. Sitzmann J.V., Wiebke E.A. Risk-reducing appendectomy and the elimination of BRCA1-associated intraperitoneal cancer. J.A.M.A. Surg. 2013; 148(3): 285-91.
  16. Taggart M.W., Galbincea J., Mansfield P.F., Fournier K.F., Royal R.E., Overman M.J.,Rashid A., Abraham S.C. High-level microsatellite instability in appendiceal carcinomas. Am. J. Surg. Pathol. 2013; 37(8): 1192-200.
  17. Shih I.M., Yan H., Speyrer D., Shmookler B.M., Sugarbaker P.H., Ronnett B.M. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei. Am. J. Surg. Pathol. 2001; 25(8): 1095-9.
  18. Tanaka H., Kobayashi T., Yoshida K., Asakura T., Taniguchi H., Mikami Y. Low-grade appendiceal mucinous neoplasm with disseminated peritoneal adenomucinosis involving the uterus, mimicking primary mucinous endometrial adenocarcinoma: a case report. J. Obstet. Gynaecol. Res. 2011; 37(11): 1726-30.
  19. Gatalica Z., Foster J.M., Loggie B.W. Low grade peritoneal mucinous carcinomatosis ass ociated with human papilloma virus infection: case report. Croat Med. J. 2008; 49(5): 669-73.
  20. Lemahieu J., D’Hoore A., Deloose S., Sciot R., Moerman P. Pseudomyxoma peritonei originating from an intestinal duplication. Case Rep. Pathol. 2013; 2013: Article ID608016.
  21. Shetty S., Thomas P., Ramanan B., Sharma P., Govindarajan V., Loggie B. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association withphenotype and prognosis. J. Surg. Res. 2013; 180(1): 97-103.
  22. Mohamed F., Gething S., Haiba M., Brun E.A., Sugarbaker P.H. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J. Surg. Oncol. 2004; 86(1): 10-5.
  23. Andréasson H., Wanders A., Sun X.F., Willén R., Graf W., Nygren P., Glimelius B., Zhang Z.Y., Mahteme H. Histopathological classification of pseudomyxoma peritonei and the prognostic importance of PINCH protein. Anticancer Res. 2012; 32(4): 1443-8.
  24. van Ruth S., Acherman Y.I., van de Vijver M.J., Hart A.A., Verwaal V.J., Zoetmulder F.A. Pseudomyxoma peritonei: a review of 62 cases. Eur. J. Surg. Oncol. 2003; 29(8): 682-8. PubMed PMID: 14511618.
  25. Baratti D., Kusamura S., Nonaka D., Langer M., Andreola S., Favaro M., Gavazzi C., Laterza B., Deraco M. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann. Surg.Oncol. 2008; 15(2): 526-34.
  26. Flatmark K., Davidson B., Kristian A., Stavnes H.T., Førsund M., Reed W. Exploring the peritoneal surface malignancy phenotype-a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum. Pathol. 2010; 41(8): 1109-19.
  27. Pulighe F., Paliogiannis P., Cossu A., Palmieri G., Colombino M., Scognamillo F., Trignano M. Molecular analysis of appendiceal mucinous cystadenoma and rectal adenocarcinoma in a patient with urothelial carcinoma: a case report. J. Med. Case Rep. 2013; 7(1): 170.
  28. Komm M., Kronawitter-Fesl M., Kremer M., Lutz L., Holinski-Feder E., Kopp R. Primary mucinous adenocarcinoma of the vermiform appendix with high grade microsatellite instability. J. Cancer. 2011; 2: 302-6.
  29. Maheshwari V., Tsung A., Lin Y., Zeh H.J. 3rd, Finkelstein S.D., Bartlett D.L. Analysis of loss of heterozygosity for tumor-suppressor genes can accurately classify and predict the clinical behavior of mucinous tumors arising from the appendix. Ann. Surg. Oncol. 2006; 13(12): 1610-6.
  30. Amstutz U., Froehlich T.K., Largiadèr C.R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011; 12(9): 1321-36.
  31. Shulman K., Cohen I., Barnett-Griness O., Kuten A., Gruber S.B., Lejbkowicz F., Rennert G. Clinical implications of UG-T1A1*28 genotype testing in colorectal cancer patients. Cancer. 2011; 117(14): 3156-62.
  32. Garcia-Carbonero R., Carnero A., Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013; 14(9): e358-69.
  33. Glasgow S.C., Yu J., Carvalho L.P., Shannon W.D., Fleshman J.W., McLeod H.L. Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. Br. J. Cancer. 2005; 92(2): 259-64.
  34. Deming D.A., Leystra A.A., Farhoud M., Nettekoven L., Clipson L., Albrecht D. et al. mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. PLoS One. 2013; 8(4): e60709.
  35. Gatalica Z., Loggie B. COX-2 expression in pseudomyxoma peritonei. Cancer Lett. 2006; 244(1): 86-90.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies